Fig. 7: Bortezomib targets to proteasome subunit coding genes to inhibit cell proliferation of NSCLC.

Under the synergistic effect of USP14, knocking out PSMD2 or treating with bortezomib can inhibit the degradation of proteasomes of p21 and p27, reduce the activity of cyclin/CDK complexes, and block the cell cycle in G0/G1 phase, thereby inhibiting the proliferation of NSCLC.